These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25514894)

  • 21. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
    Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aripiprazole in the treatment of delirium.
    Straker DA; Shapiro PA; Muskin PR
    Psychosomatics; 2006; 47(5):385-91. PubMed ID: 16959926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Classics in Chemical Neuroscience: Aripiprazole.
    Casey AB; Canal CE
    ACS Chem Neurosci; 2017 Jun; 8(6):1135-1146. PubMed ID: 28368577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
    Bruins Slot LA; Bardin L; Auclair AL; Depoortere R; Newman-Tancredi A
    Behav Pharmacol; 2008 Mar; 19(2):145-52. PubMed ID: 18332679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats.
    Jantschak F; Brosda J; Franke RT; Fink H; Möller D; Hübner H; Gmeiner P; Pertz HH
    J Pharmacol Exp Ther; 2013 Oct; 347(1):57-68. PubMed ID: 23863695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors.
    Ueda T; Ugawa S; Ishida Y; Shimada S
    Eur J Pharmacol; 2011 Dec; 671(1-3):79-86. PubMed ID: 21951966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aripiprazole and haloperidol in the treatment of delirium.
    Boettger S; Friedlander M; Breitbart W; Passik S
    Aust N Z J Psychiatry; 2011 Jun; 45(6):477-82. PubMed ID: 21563866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Atypical antipsychotic efficacy and safety in managing delirium: a systematic review and critical analysis].
    Pelland C; Trudel JF
    Psychol Neuropsychiatr Vieil; 2009 Jun; 7(2):109-19. PubMed ID: 19473954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perospirone in the treatment of patients with delirium.
    Takeuchi T; Furuta K; Hirasawa T; Masaki H; Yukizane T; Atsuta H; Nishikawa T
    Psychiatry Clin Neurosci; 2007 Feb; 61(1):67-70. PubMed ID: 17239041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aripiprazole in the treatment of delirium.
    Alao AO; Soderberg M; Pohl EL; Koss M
    Int J Psychiatry Med; 2005; 35(4):429-33. PubMed ID: 16673842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients.
    Boettger S; Breitbart W
    Palliat Support Care; 2011 Dec; 9(4):351-7. PubMed ID: 22104410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A new approach to the treatment of delirium: atypical antipsychotics].
    Onur E; Cimilli C
    Turk Psikiyatri Derg; 2005; 16(3):216-24. PubMed ID: 16180154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Costentin J
    Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
    Newman-Tancredi A
    Curr Opin Investig Drugs; 2010 Jul; 11(7):802-12. PubMed ID: 20571976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
    Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
    Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.